Hong Kong-based cross-border healthcare investment firm Ally Bridge Group has completed investments in two European biopharmaceutical companies, Galenica AG of Switzerland and Nabriva of Austria and the U.S., further expanding the firm’s global portfolio.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?